Compare CHCT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | DSGN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.6M | 418.1M |
| IPO Year | 2015 | 2021 |
| Metric | CHCT | DSGN |
|---|---|---|
| Price | $15.26 | $9.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $13.50 |
| AVG Volume (30 Days) | 323.0K | ★ 538.4K |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 12.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,547,000.00 | N/A |
| Revenue This Year | $6.97 | N/A |
| Revenue Next Year | $5.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.40 | N/A |
| 52 Week Low | $13.23 | $2.60 |
| 52 Week High | $20.87 | $10.31 |
| Indicator | CHCT | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 71.98 |
| Support Level | $15.18 | $8.58 |
| Resistance Level | $15.91 | $9.85 |
| Average True Range (ATR) | 0.45 | 0.66 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 56.77 | 86.62 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.